Home - Synopulse

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

Athithi July 16, 2026

DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A…

Germany has passed healthcare reforms despite pharma's resistance, hiking the fixed rebate on branded drugs from 7% to 15.5% to save €16.3 billion next year.

Germany Defies Pharma Backlash, Hikes Drug Rebate to 15.5%

FTC Forces Caremark to Unlock $13B in Patient Savings

The Pulse - Biopharma this Week (july 6 - 12, 2026)

The Pulse – Biopharma Week in Review: Vertex’s $10B Deal, Keytruda Bladder Win

Two New Non-Invasive Tests Could Slash the Wait for an Endometriosis Diagnosis

Editor’s Feature

NextGen Gene Editing Breakthroughs Redefine Personalized Care

Shajini November 4, 2025

Monthly Standout

The Pulse – Biopharma Week in Review: Vertex’s $10B Deal, Keytruda Bladder Win

Athithi July 13, 2026

February 2026 Deal Report: Five Signals from $53B in Activity

Shajini March 1, 2026

NextGen Gene Editing Breakthroughs Redefine Personalized Care

Shajini November 4, 2025

The Signal

7 Market Access Trends Reshaping Pharma by 2027

Athithi June 3, 2026

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Shajini May 27, 2026

No post found!

NeuroPulse

NeuroPulse Wk 26: Cockayne Gene Therapy World-First

June 29, 2026

Neuropulse Daily: January 8, 2026

January 8, 2026

NeuroPulse Daily: January 05, 2026

January 6, 2026

NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets

December 20, 2025

NeuroPulse Daily Brief: December 20, 2025

December 20, 2025

NeuroPulse Today’s Signals: Precision Regulation, RNA Partnerships, and Real-World Data Redefine Neuro Strategy

December 19, 2025

AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform

July 2, 2026

Korea Unlocks Breakthrough Access for Ultomiris and Jemperli

December 2, 2025

Deal Room

AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform

July 2, 2026

Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager

June 30, 2026

Metsera responds to Pfizer lawsuit, defends board process in Novo bid dispute

November 3, 2025

Valo Health, Merck KGaA Launch $3B+ AI Collaboration Targeting Parkinson’s Disease

Novo’s unsolicited bid for Metsera challenges Pfizer pact

November 3, 2025

Thermo Fisher’s Inspiring $10 Billion Acquisition of Clario

October 29, 2025

Access Watch

FTC Forces Caremark to Unlock $13B in Patient Savings

July 15, 2026

German Court Blocks Merck’s Subcutaneous Keytruda Rollout, Escalating Patent Fight With Halozyme

German Court Halts Merck’s Keytruda SC in Major Patent Clash

December 9, 2025

Germany Defies Pharma Backlash, Hikes Drug Rebate to 15.5%

July 15, 2026

NHS Gives Green Light to Life-Changing SMA Treatments

May 15, 2026

EU Critical Medicines Act Fights Dangerous Supply Crisis

May 11, 2026

What’s Next

Two New Non-Invasive Tests Could Slash the Wait for an Endometriosis Diagnosis

July 8, 2026

AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform

July 2, 2026

Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager

June 30, 2026

NeuroPulse Wk 26: Cockayne Gene Therapy World-First

June 29, 2026